Literature DB >> 7680304

Location of nitroblue tetrazolium-reducing activity in human colonic mucosa obtained by biopsy.

N Oshitani1, A Kitano, H Okabe, S Nakamura, T Matsumoto, K Kobayashi.   

Abstract

The location of nitroblue tetrazolium-reducing activity was studied in colonic biopsy specimens from 28 patients with ulcerative colitis and from 23 controls. Nitroblue tetrazolium was reduced by epithelial cells, vascular endothelium, and interstitial mononuclear cells of the colonic mucosa from both groups. Blue formazan, a reduced form of nitroblue tetrazolium, was seen faintly after 30 min of culture; the amount increased up to 2 hr tested. The vascular endothelium of the patients with ulcerative colitis reduced nitroblue tetrazolium significantly more than that of the controls. The reduction of nitroblue tetrazolium was graded from 0 to 3 and was 1.0 +/- 0.6 in the controls, 1.6 +/- 0.8 in ulcerative colitis patients (P < 0.05), 1.9 +/- 0.7 (P < 0.01) in patients with active ulcerative colitis, and 1.4 +/- 0.9 in patients with inactive ulcerative colitis (difference not significant). Aggregates of mononuclear cells that reduced nitroblue tetrazolium were found in 10 of 28 patients with ulcerative colitis but not in the controls.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 7680304     DOI: 10.1007/bf01316513

Source DB:  PubMed          Journal:  Dig Dis Sci        ISSN: 0163-2116            Impact factor:   3.199


  19 in total

1.  Physical and metabolic factors in diffusion of solutes into tissue slices.

Authors:  J CASCARANO; B W ZWEIFACH
Journal:  Am J Physiol       Date:  1961-06

2.  Comparative histochemical and quantitative study of adrenal and kidney tissue by tetrazolium technique.

Authors:  J CASCARANO; B W ZWEIFACH
Journal:  J Histochem Cytochem       Date:  1955-09       Impact factor: 2.479

3.  In vivo visualization of oxyradical-dependent photoemission during endothelium-granulocyte interaction in microvascular beds treated with platelet-activating factor.

Authors:  M Suematsu; I Kurose; H Asako; S Miura; M Tsuchiya
Journal:  J Biochem       Date:  1989-08       Impact factor: 3.387

4.  Toxic oxygen metabolite production by circulating phagocytic cells in inflammatory bowel disease.

Authors:  J G Williams; L E Hughes; M B Hallett
Journal:  Gut       Date:  1990-02       Impact factor: 23.059

5.  Macrophage subpopulations in lamina propria of normal and inflamed colon and terminal ileum.

Authors:  Y R Mahida; S Patel; P Gionchetti; D Vaux; D P Jewell
Journal:  Gut       Date:  1989-06       Impact factor: 23.059

6.  Acid hydrolases in monocytes from patients with inflammatory bowel disease, chronic liver disease, and rheumatoid arthritis.

Authors:  N K Ganguly; J G Kingham; B Lloyd; R S Lloyd; C P Price; D R Triger; R Wright
Journal:  Lancet       Date:  1978-05-20       Impact factor: 79.321

7.  Xanthine oxidase from liver and duodenum of the rat: histochemical localization and electrophoretic heterogeneity.

Authors:  M L Sackler
Journal:  J Histochem Cytochem       Date:  1966-04       Impact factor: 2.479

8.  Respiratory burst activity of intestinal macrophages in normal and inflammatory bowel disease.

Authors:  Y R Mahida; K C Wu; D P Jewell
Journal:  Gut       Date:  1989-10       Impact factor: 23.059

9.  Xanthine oxidase activity in rat pulmonary artery endothelial cells and its alteration by activated neutrophils.

Authors:  S H Phan; D E Gannon; J Varani; U S Ryan; P A Ward
Journal:  Am J Pathol       Date:  1989-06       Impact factor: 4.307

10.  Heterogeneity of HLA-DR-positive histiocytes in human intestinal lamina propria: a combined histochemical and immunohistological analysis.

Authors:  W S Selby; L W Poulter; S Hobbs; D P Jewell; G Janossy
Journal:  J Clin Pathol       Date:  1983-04       Impact factor: 3.411

View more
  1 in total

Review 1.  NADPH oxidases in Parkinson's disease: a systematic review.

Authors:  Karim Belarbi; Elodie Cuvelier; Alain Destée; Bernard Gressier; Marie-Christine Chartier-Harlin
Journal:  Mol Neurodegener       Date:  2017-11-13       Impact factor: 14.195

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.